was approved in Europe in September as a subcutaneous injection offering a patient-friendly quarterly dosing schedule, as opposed to fortnightly and sometimes monthly dosing for Cimzia injections.

The US FDA has approved a label extension for UCB’s Cimzia (certolizumab pegol) for adults with moderate-to-severe plaque psoriasis, marking the company’s entry into immuno-dermatology ...